Cytochrome P450 17A1 Inhibitor drugs compared
Compare all 3 Cytochrome P450 17A1 Inhibitor drugs side by side, used for conditions such as prostatic neoplasms, castration-resistant. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.
Full ranking · 3 drugs
- 172/100
abiraterone acetate
Abiraterone Acetate
- 2New
yonsa
Abiraterone Acetate
- 3New
zytiga
Abiraterone Acetate
Frequently asked questions
What is the Cytochrome P450 17A1 Inhibitor drug class?
Cytochrome P450 17A1 Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 3 Cytochrome P450 17A1 Inhibitor products, each independently rated.
Are all Cytochrome P450 17A1 Inhibitor drugs the same?
No. Cytochrome P450 17A1 Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.
What conditions do Cytochrome P450 17A1 Inhibitor drugs treat?
Per NIH RxClass drug-classification data, Cytochrome P450 17A1 Inhibitor drugs are used for conditions including prostatic neoplasms, castration-resistant.
Sources: the Cytochrome P450 17A1 Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.